These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T. World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488 [Abstract] [Full Text] [Related]
3. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610. Urakawa H, Nagano A, Machida R, Tanaka K, Kataoka T, Sekino Y, Nishida Y, Takahashi M, Kunisada T, Kawano M, Yoshida Y, Takagi T, Sato K, Hiruma T, Hatano H, Tsukushi S, Sakamoto A, Akisue T, Hiraoka K, Ozaki T. Jpn J Clin Oncol; 2022 Sep 18; 52(9):1021-1028. PubMed ID: 35472141 [Abstract] [Full Text] [Related]
4. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center. Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W. J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187 [Abstract] [Full Text] [Related]
5. The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS. Bone Joint J; 2021 Jan 17; 103-B(1):184-191. PubMed ID: 33380180 [Abstract] [Full Text] [Related]
6. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage. Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM. J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866 [Abstract] [Full Text] [Related]
11. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Lancet Oncol; 2019 Dec 21; 20(12):1719-1729. PubMed ID: 31704134 [Abstract] [Full Text] [Related]
12. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA. Ann Surg Oncol; 2015 Sep 21; 22(9):2860-8. PubMed ID: 26033180 [Abstract] [Full Text] [Related]
14. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review. Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C. Clin Orthop Relat Res; 2020 May 21; 478(5):1076-1085. PubMed ID: 31794487 [Abstract] [Full Text] [Related]
17. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery. Asano N, Saito M, Kobayashi E, Morii T, Kikuta K, Watanabe I, Anazawa U, Takeuchi K, Suzuki Y, Susa M, Nishimoto K, Ishii R, Miyazaki N, Mrioka H, Kawai A, Horiuchi K, Nakayama R. Ann Surg Oncol; 2022 Jun 21; 29(6):3992-4000. PubMed ID: 35175454 [Abstract] [Full Text] [Related]